Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry

被引：0
|
作者：
Fiore, Stefano [1 ]
Chen, Lang [2 ]
Clinton, Cassie [2 ]
Yun, Huifeng [2 ]
Praestgaard, Amy [3 ]
Ford, Kerri [3 ]
Curtis, Jeffrey R. [2 ]
机构：
[1] Sanofi, Bridgewater, NJ USA
[2] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
[3] Sanofi, Cambridge, MA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0834
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Predicting Disease Activity in Rheumatoid Arthritis Patients Using Machine Learning: Data from the ACR's RISE Registry
    Tshimanga, Eren-Ajani
    Gianfrancesco, Milena
    Giampanis, Stefanos
    Li, Jing
    Kersey, Emma
    Yazdany, Jinoos
    Norgeot, Beau
    Schmajuk, Gabriela
    Izadi, Zara
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1789 - 1790
  • [22] Disease activity correlates and functionality in patients with rheumatoid arthritis - real-world experience from a South Asian country
    Nasir, Noreen
    Majid, Hafsa
    Khan, Ayesha Habib
    Awan, Safia
    Riaz, Mohammed Mehmood
    REUMATOLOGIA, 2022, 60 (03): : 183 - 191
  • [23] Comparison of Real-World Treatment Patterns for Patients Newly Diagnosed with Ulcerative Colitis or Crohn's Disease Who Receive Early vs Late Biologic Therapy
    Siegel, Corey A.
    Nero, Damion
    Shi, Nianwen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S404 - S404
  • [24] Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry
    Mease, Philip J.
    Blauvelt, Andrew
    Sima, Adam P.
    Beaty, Silky W.
    Low, Robert
    Gomez, Braulio
    Gurrola, Marie
    Lebwohl, Mark G.
    DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2805 - 2825
  • [25] COMPARISON OF REAL-WORLD PERSISTENCE OF SUBCUTANEOUSLY ADMINISTERED BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPIES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS (RA) SWITCHING FROM ANOTHER BIOLOGIC
    Best, Jennie H.
    Tominna, Lenore
    Abbass, Ibrahim
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1129 - 1129
  • [26] Long-Term Effectiveness and Safety of Infliximab in Rheumatoid Arthritis Patients: Real-World Data from the Biologic Treatment Registry Across Canada (BioTRAC)
    Olszynski, Wojciech
    Rahman, Proton
    Chow, Andrew
    Arendse, Regan
    Choquette, Denis
    Jaroszynska, Anna
    Sholter, Dalton
    Dixit, Sanjay
    Baer, Philip
    Kelsall, John
    Rampakakis, Emmanouil
    Osborne, Brendan
    Asin-Milan, Odalis
    Lehman, Allen
    Nantel, Francois
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 786 - 786
  • [27] Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry
    Koh, J. H.
    Lee, S-K
    Kim, J.
    Kim, H-A
    Shin, K.
    Min, J-K
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 269 - 278
  • [28] Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World US Data
    Gharaibeh, Mahdi
    Bonafede, Machaon
    McMorrow, Donna
    Hernandez, Ervant J. Maksabedian
    Stolshek, Bradley S.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (08): : 1039 - +
  • [29] REAL-WORLD TREATMENT PERSISTENCE WITH BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS AMONG GERMAN PATIENTS WITH PSORIATIC ARTHRITIS
    Sewerin, P.
    Borchert, K.
    Meise, D.
    Mahlich, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1172 - 1172
  • [30] CHARACTERISTICS AND 6-MONTH OUTCOMES AMONG REAL-WORLD PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING UPADACITINIB: ANALYSIS FROM THE CORRONA REGISTRY
    Kremer, J. M.
    Tundia, N.
    McLean, R.
    Blachley, T.
    Maniccia, A.
    Pappas, D. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 446 - 446
12345